PEG Fusion for Peripheral Nerve Injury
Trial Summary
What is the purpose of this trial?
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagent to promote nerve regeneration in humans. Therefore, the goal of this Phase 2a clinical trial is to establish safety data and to examine the effect of PEG fusion on clinical outcomes including recovery of sensory and motor function. Results will be externally validated using data collected in the DoD funded prospective NERVE study and will provide preliminary evidence to power a larger phase II efficacy trial.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment NTX-001, Polyethylene Glycol (PEG) Mediated Fusion, for peripheral nerve injury?
Research shows that PEG fusion can rapidly restore nerve function and improve recovery in animal models with nerve injuries. In cases of nerve damage, PEG fusion has been shown to quickly reestablish nerve connections and improve sensory and motor recovery, suggesting it could be a promising treatment for peripheral nerve injuries.12345
Is PEG Fusion safe for humans?
PEG Fusion has been used in animal studies and early human case reports for nerve repair, showing promising results in restoring nerve function. However, some patients experienced side effects like swelling and scar development, which improved over time. Overall, the safety data is limited but suggests potential for safe use with careful monitoring.12356
How is the PEG Fusion treatment different from other treatments for peripheral nerve injury?
PEG Fusion is unique because it rapidly restores axonal continuity and improves sensory and motor recovery by fusing severed nerve ends, unlike traditional methods that rely on slow axonal regrowth. This approach prevents muscle atrophy and Wallerian degeneration, leading to faster and more effective recovery.12345
Research Team
Jaimie Shores, MD
Principal Investigator
Johns Hopkins University
Eligibility Criteria
This trial is for adults aged 18-80 with acute upper extremity peripheral nerve injuries, specifically to the axillary, radial, median, ulnar, or musculocutaneous nerves. Candidates must present within 48 hours of injury and have both sensory and motor function impairment. Exclusions include brachial plexus injuries, purely sensory nerve damage beyond the wrist, previous neurological disorders or trauma, severe psychiatric conditions that could affect follow-up compliance or pose a self-harm risk.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive either PEG mediated reconstruction or conventional nerve reconstruction within 24 hours of injury
Initial Follow-up
Participants are monitored for complications or problems within the first 30 days post-surgery
Extended Follow-up
Participants are monitored for recovery of sensory and motor function, pain, range of motion, and patient satisfaction
Treatment Details
Interventions
- NTX-001
- PEG Fusion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Major Extremity Trauma Research Consortium
Lead Sponsor
United States Department of Defense
Collaborator